New drug combo aims to fight Hard-to-Treat cancers

NCT ID NCT06708663

Recruiting now Disease control Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combination shrinks tumors. Participants must have failed prior therapy or have no standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HX009 and IN10018 (two experimental drugs given together, sometimes with standard chemotherapy)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced biliary tract cancer or melanoma that has not responded to standard therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so the drugs may not work or could cause serious side effects. The combination is experimental and not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER MELANOMA

Contacts and locations

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.